Cytokinetics (NASDAQ: CYTK) reported Q4 basic EPS of $0.16, $0.43 better than the analyst estimate of ($0.27), may not compare. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $16.33 million.

GUIDANCE:

Cytokinetics sees FY 2017 cash revenue of $21-23 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.